Cytori Technology Selected for NHLBI Funded Trial in LVAD Patients

The CCTRN is supported by grants from the National Heart, Lung, and . This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient's heart muscle 60 to 90 days after placement of an LVAD.

http://ift.tt/1o50Nwo